Vaxart Inc VXRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
-
Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
-
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
Trading Information
- Previous Close Price
- $0.79
- Day Range
- $0.77–0.85
- 52-Week Range
- $0.52–1.54
- Bid/Ask
- $0.80 / $0.82
- Market Cap
- $183.77 Mil
- Volume/Avg
- 31,610 / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 109
- Website
- https://www.vaxart.com
Comparables
Valuation
|
Metric
|
VXRT
|
02509
|
SVA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 23.52 |
Price/Book Value | 2.30 | 35.46 | 1.82 |
Price/Sales | 8.49 | 108.80 | 1.83 |
Price/Cash Flow | — | — | 8.10 |
Price/Earnings
VXRT
02509
SVA
Financial Strength
|
Metric
|
VXRT
|
02509
|
SVA
|
|---|---|---|---|
Quick Ratio | 4.28 | 1.70 | 11.22 |
Current Ratio | 4.54 | 1.86 | 11.39 |
Interest Coverage | −30.10 | −18.42 | −59.95 |
Quick Ratio
VXRT
02509
SVA
Profitability
|
Metric
|
VXRT
|
02509
|
SVA
|
|---|---|---|---|
Return on Assets (Normalized) | −61.64% | −47.40% | −0.81% |
Return on Equity (Normalized) | −92.00% | −341.08% | −1.25% |
Return on Invested Capital (Normalized) | −71.33% | −56.34% | −1.48% |
Return on Assets
VXRT
02509
SVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cwmrpkvvjv | Ywmt | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qhlrwmq | Hbgfvf | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjhvvjgp | Ptxfqdq | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mddmmlqp | Rjwyy | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Brcbspbzl | Zshd | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Lkqgphpq | Nmjf | $28.0 Bil | |||
| Moderna Inc
MRNA
| Ynydnmjz | Gwplg | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Bgqbkxflf | Crwt | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cmcqqswfl | Mtmllx | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Psqqdysml | Djlvcwt | $12.6 Bil |
United States